News | RIVM

From 1 October 2023, heel prick test also screens for metabolic disorder ALD

From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.

NIPT available as standard option for all pregnant women from 1 April

From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.

Cancer screening programmes now more accessible to transgender and intersex persons

Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.

From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26

From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.

Tailor-made information will help immigrants make decisions on taking part in screening programmes

Immigrants are relatively less likely to take part in preventive screening programmes, such as cancer screening. This is partly due to the language barrier and a lack of knowledge, according to a doctoral thesis by Nora Hamdiui.

Breast cancer screening resumes on Bonaire after COVID-19 hiatus

Women aged 50 to 75 years on Bonaire can participate in the breast cancer screening programme again as of Wednesday, May 26, 2021. This was temporarily halted in 2020 due to the COVID-19 pandemic.

Population screening programmes temporarily on hold

Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.

Discussion regarding health-based guidance value of PFOA

The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).

Blood spot test extended as of 1 January 2017 to include two more disorders

As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.

Newborn heel prick screening starts on St Eustatius and Saba

On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.